Phase III data for dapirolizumab pegol presented at the 2025 American College of Rheumatology showed quality-of-life benefits ...

Early initiation of TNF inhibitors among children with non-sJIA led to significant and sustained improvements in disease activity.

Medical board-style questions created by AI and large language models were often grammatically correct but factually ...

Disease activity and multimorbidity among patients in the US with PsA varied based on geographic region, socioeconomic deprivation, race, and gender.

Fibromyalgia was considered a comorbidity rather than a rheumatic disease, but was present in about 10% of patients. Other ...

The Lupus Foundation of America (LFA) celebrated exceptional lupus researchers at the 20th Anniversary Evelyn V. Hess ...

I recently had the privilege of speaking at the Advances in Rheumatology and Technologies Symposium (ARTS), held in Chicago ...

The current recommended urine protein to creatinine ratio is arbitrary, and a lower bar would capture more lupus nephritis ...

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid ...

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS ...

Highlights of the rese-cel clinical and translational data being presented at ACR Convergence 2025 as of the data cut-off date of September 11, 2025, and development updates include: ...

Opioid prescribing appears to be prevalent among older adults with rheumatic diseases, according to results presented at the American College of Rheumatology (ACR) Convergence 2025.